“Instructions on how to inject Retacrit yourself” can be found at the end of the package leaflet.Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.Patients who develop pure red cell aplasia (PRCA) following treatment with any erythropoietin should not receive Retacrit or any other erythropoietin (see section 4.4).All contraindications associated with autologous blood predonation programmes should be respected in patients being supplemented with Retacrit.The use of Retacrit in patients scheduled for major elective orthopaedic surgery and not participating in an autologous blood predonation programme is contraindicated in patients with severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident.Surgery patients who for any reason cannot receive adequate antithrombotic prophylaxis.In all patients receiving epoetin zeta, blood pressure should be closely monitored and controlled. For the once weekly epoetin alfa treatment group, a total of 76 men (45%) and 92 women (55%) between the ages of 20 and 88 years were treated. Epoetin alfa (Epogen®; Procrit®; Retacrit™) Non-Dialysis Prior Auth Criteria Proprietary Information. A less defined profile was observed for RBCs and haemoglobin. • decreased locoregional control in patients with advanced head and neck cancer receiving radiation therapy when administered to achieve a haemoglobin concentration level of greater than 14 g/dL (8.7 mmol/L), Particular attention should be paid to sudden stabbing migraine-like headaches as a possible warning signal (see section 4.8).Epoetin zeta should be used with caution in patients with epilepsy, history of seizures, or medical conditions associated with a predisposition to seizure activity such as CNS infections and brain metastases.Epoetin zeta should be used with caution in patients with chronic liver failure. More than 95% of patients were able to avoid RBC transfusions. Follow your healthcare provider's instructions about how you should inject Retacrit. This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e.
Dose selection and adjustment for an elderly patient should be individualized to achieve and maintain the target hemoglobin Among 778 patients enrolled in the 3 clinical studies of epoetin alfa for the treatment of anemia due to concomitant chemotherapy, 419 received epoetin alfa and 359 received placebo. When giving subcutaneous injections, follow your healthcare provider’s instructions about changing the site for each injection. These studies have shown a consistent unexplained statistically significant excess mortality in patients who have anaemia associated with various common cancers who received recombinant human erythropoietin compared to controls. If the medicinal product has not been used at the end of this period, it should be disposed of.Store in the original package in order to protect from light.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.Pre-filled syringe Type I glass with a fixed steel injection needle and a plunger stopper with PTFE coating with or without a needle guard or needle-trap device.